Veracyte reports preliminary Q4 revenue $138M-$140M, consensus $131.75M

“I am immensely proud of the impact our tests have had on the more than 800,000 patients we have served since the company’s inception,” said Marc Stapley, Veracyte’s (VCYT) chief executive officer. “We ended 2025 with another strong quarter of testing revenue growth and further expanded our patient impact. Looking ahead to 2026, I’m excited for continued Decipher and Afirma growth, as well as the launch of Prosigna and our TrueMRD platform in the US market, which we believe will further catalyze our patient reach and financial performance.”